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Abstract
Obesity is a risk factor for advanced, but not localised, prostate cancer (PCa), and for
poor prognosis. However, the detection of localised PCa through asymptomatic
screening might influence these associations. We investigated height and body mass
index (BMI) among 431 902 men in five Swedish cohorts in relation to PCa risk,
according to cancer risk category and detection mode, and PCa-specific mortality
using Cox regression. Statistical tests were two-sided. Height was positively associ-
ated with localised intermediate-risk PCa (HR per 5 cm, 1.03, 95% CI 1.01-1.05),
while overweight and obesity were negatively associated with localised low- and
intermediate-risk PCa (HRs per 5 kg/m2, 0.86, 95% CI 0.81-0.90, and 0.92, 95% CI
0.88-0.97). However, these associations were partially driven by PCa's detected by
asymptomatic screening and, for height, also by symptoms unrelated to PCa. The HR
of localised PCa's, per 5 kg/m2, was 0.88, 95% CI 0.83 to 0.92 for screen-detected
PCa's and 0.96, 95% CI 0.90 to 1.01 for PCa's detected through lower urinary tract
symptoms. BMI was positively associated with PCa-specific mortality in the full pop-
ulation and in case-only analysis of each PCa risk category (HRs per 5 kg/m2,
1.11-1.22, P for heterogeneity = .14). More active health-seeking behaviour among
tall and normal-weight men may partially explain their higher risk of localised PCa.
The higher PCa-specific mortality among obese men across all PCa risk categories in
our study suggests obesity as a potential target to improve the prognosis of obese
PCa patients.
K E YWORD S
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1 | INTRODUCTION
Obesity is an established risk factor for several cancer forms,1 but the
association with prostate cancer (PCa) is complex. While high body
mass index (BMI), a marker of general obesity, has been negatively
Abbreviations: 95% CI, 95% confidence interval; BMI, body mass index; HR, hazard ratio;
LUTS, lower urinary tract symptoms; PCa, prostate cancer; PSA, prostate-specific antigen.
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related to the risk of localised and low-grade PCa's, it has been
unrelated or positively related to the risk of advanced and high-grade
PCa's.2-7 However, it has been suggested that these results are
influenced by delayed detection of PCa in obese men due to their
hemodiluted prostate-specific antigen (PSA) levels and enlarged pros-
tate gland, and possibly lower frequency of asymptomatic PCa screen-
ing, which primarily detects localised PCa's.8-10 Observational studies
have revealed positive associations between height and PCa risk.3,4,11
Apart from one Mendelian randomisation study supporting a slight
positive association between height, but not BMI, and advanced PCa
risk,10 another Mendelian randomisation study of BMI10,11 did not
confirm findings of observational studies, suggesting that obesity and
height have no causal role in PCa risk.
The potential role of obesity as prognostic risk factor for PCa is
supported by both population studies and patient studies, which indi-
cate higher PCa-specific mortality with higher BMI.12-16 These find-
ings are further supported by studies of BMI and biochemical
recurrence after radical prostatectomy.16-18 However, most prognos-
tic studies have been based on patients with body weight measured
after the PCa diagnosis, which limits causal inference, as the cancer or
awareness of the cancer might have caused change in weight. More-
over, studies investigating the prognostic role of obesity across a
wider clinical range of PCa's are lacking.
We investigated prediagnostic body size in relation to PCa risk
and prognosis across early and late disease stages in a large, pooled
cohort study. The specific aim was to investigate the association of
height and BMI, with the risk of PCa according to cancer risk category
and symptomatic and asymptomatic detection of localised tumours,
and with PCa-specific mortality overall and across cancer risk
categories.
2 | MATERIAL AND METHODS
2.1 | Study population
The study included men in five Swedish cohorts, one including con-
struction workers from the whole of Sweden, and four population-
based cohorts in northern or southern Sweden, as further described in
the Supporting Information. The cohorts included information from
health examinations, including measurements of height and weight,
performed in 1971 to 2016. Cohort participants were followed in
national registers until December 31, 2016. The Swedish Cancer Reg-
ister19 was used for the identification of cancer diagnoses, and the
Swedish Cause of Death Register20 was used to obtain information
on death and its cause. Both registers have virtually complete cover-
age of the Swedish population.
PCa cases were further linked to the National Prostate Cancer
Register (NPCR) of Sweden to obtain information on tumour charac-
teristics and primary treatment.21,22 Since January 1, 1998, the NPCR
has captured on average 98% of PCa cases as compared to the Cancer
Register. Validity is high, with, for example, more than 95% agreement
with medical records for Gleason score, lymph node metastasis and
bone metastasis.22 Between 1987 and 1998, the register also includes
information from regional PCa registers. PCa's were classified into five
risk groups: localised low-risk (T1-2, Gleason score 2-6 and PSA
< 10 ng/mL), localised intermediate-risk (T1-2, Gleason score 7 and/or
PSA 10 to <20 ng/mL), localised high-risk (T3 and/or Gleason score
8-10 and/or PSA 20 to <50 ng/mL), regionally metastatic/locally
advanced (T4 and/or N1 and/or PSA 50 to <100 ng/mL in the
absence of distant metastases [M0 or Mx]) or distant metastases
(M1 and/or PSA ≥100 ng/mL).21 PCa risk was also analysed by stage
and grade. We also used information in the PCa register from 2004
onwards on the main reason for PCa detection: health control includ-
ing PSA screening (asymptomatic screening), lower urinary tract symp-
toms (LUTS) or other symptoms. Validation of these data has shown
some misclassification but less for asymptomatic screening and LUTS
than for other symptoms.22
Information on further register linkages performed to obtain co-
variable data and the selection criteria for the study are provided in
Supporting Information Appendix A and Figure S1. The study was
approved by the Ethics Committee at Lund University, Sweden
(No. 2016/564), and informed consent was obtained.
2.2 | Statistical analysis
The full study population of 431 902 men were pooled in a Cox
regression analysis with attained age as time scale to estimate hazard
ratios (HRs) and 95% confidence intervals (CI) of incident PCa and
PCa-specific mortality according to height and BMI. Interaction tests
between height and BMI with cohort did not indicate any differential
associations by cohort, supporting the pooling of data. Participants
were followed until the date of event, emigration, death or in incident
analysis, until censoring due to another cancer diagnosis (excluding
nonmelanoma skin cancer), or until end of follow-up, whichever came
first. Models were stratified by cohort and birth period, and adjusted
What's new?
While body mass index and height are linked to prostate
cancer risk, how these factors are related to specific risk cat-
egories, including localized and advanced disease, remains
uncertain. In this investigation of body size and prostate can-
cer risk, height was positively associated with localised,
intermediate-risk prostate cancer, and overweight and obe-
sity were associated with lower risks of localised low- and
intermediate-risk prostate cancers. These associations were
partially driven by asymptomatic screening, suggesting that
increased screening behavior among tall and normal-weight
men contributes to their elevated risk of localised prostate
disease. Relatively high prostate cancer-specific mortality
among obese men flags elevated BMI as a key prognostic
factor for prostate malignancy.
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TABLE 1 Baseline characteristics of the 431 902 men included in the study, in total and according to subsequent case status
Baseline characteristic Total (n = 431 902) Noncases (n = 399 031)
Prostate cancer
cases (n = 32 871)
Cohort (year of baseline examination), n (%)
Construction Workers Cohort (1971-1993) 345 816 (80) 319 329 (80) 26 487 (81)
Västerbotten Intervention Programme (1985-2016) 55 653 (13) 52 620 (13) 3033 (9)
Northern Sweden Monica Study (1986-2014) 4004 (1) 3747 (1) 257 (1)
Malmö Diet and Cancer Study (1991-1996) 11 622 (3) 9999 (3) 1623 (5)
Malmö Preventive Project (1974-1984) 14 807 (3) 13 336 (3) 1471 (4)
Age, years
Mean (SD) 37.5 (13.6) 37.0 (13.6) 43.6 (12.5)
Categories, n (%)
<35 209 363 (49) 199 717 (50) 9646 (29)
35-44 87 600 (20) 79 897 (20) 7703 (24)
45-54 74 025 (17) 65 800 (17) 8225 (25)
≥55 60 914 (14) 53 617 (13) 7297 (22)
Height, cm
Mean (SD) 177.6 (6.6) 177.7 (6.6) 176.7 (6.3)
Categories, n (%)
<175 140 157 (32) 127 967 (32) 12 190 (37)
175-179 126 255 (29) 116 278 (29) 9977 (30)
180-184 102 307 (24) 95 155 (24) 7152 (22)
185-190 46 770 (11) 43 988 (11) 2782 (9)
>190 16 413 (4) 15 643 (4) 770 (2)
Body mass index, kg/m2
Mean (SD) 24.6 (3.4) 24.6 (3.4) 24.9 (3.0)
Categories, n (%)
<22.5 122 300 (28) 115 102 (29) 7198 (22)
22.5-24.9 135 792 (31) 124 916 (31) 10 876 (33)
25-27.4 100 791 (23) 91 667 (23) 9124 (28)
27.5-29.9 45 181 (11) 41 389 (10) 3792 (11)
≥30 27 838 (7) 25 957 (7) 1881 (6)
Smoking status, n (%)
Never smoker 168 711 (39) 157 876 (39) 10 835 (33)
Ex-smoker 70 044 (16) 62 715 (16) 7329 (22)
Current smoker 132 874 (31) 123 313 (31) 9561 (29)
Missinga 60 273 (14) 55 127 (14) 5146 (16)
Education, n (%)b
Pre-upper secondary school <9 years 113 421 (26) 99 477 (25) 13 944 (42)
Pre-upper secondary school 9 years 38 168 (9) 36 177 (9) 1991 (6)
Max. 2 years upper secondary school 160 217 (37) 152 138 (38) 8079 (25)
3 years upper secondary school 46 624 (11) 42 238 (10) 4386 (13)
Post-upper secondary school <3 years 24 115 (5) 22 626 (6) 1489 (5)
Post-upper secondary school ≥3 years 15 937 (4) 14 851 (4) 1086 (3)
Missing 33 420 (8) 31 524 (8) 1896 (6)
Country of birth, n (%)
Born in Sweden and both parents born in Sweden 385 632 (89) 355 061 (89) 30 571 (93)
Other 46 270 (11) 43 970 (11) 2300 (7)
(Continues)
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for baseline age, baseline smoking status, healthcare region, country
of birth and education. The shape of the associations between height
and BMI, and PCa risk was modelled using restricted cubic splines.
Among men with incident PCa, HRs of PCa-specific mortality by
height and BMI levels were estimated using Cox regression with time
since diagnosis as the time scale. The same strata and adjustments
were used for smoking, healthcare region, and country of birth as in
the full population analysis, and models were additionally adjusted for
age at PCa diagnosis, education at time of diagnosis, income closest
to diagnosis, source of income closest to diagnosis, civil status closest
to diagnosis, Charlson comorbidity index,23 primary treatment for PCa
and PCa risk category (in the total analysis). Details on the adjustment
for confounders (continuous or categories) are described in
Supporting Information Appendix A.
As long-term intra-individual fluctuations and random measure-
ment error of BMI dilute HRs, these were corrected for the regression
dilution ratio (RDR) of 0.90 for BMI, calculated as described by Wood
et al.24 HRs were corrected by HRcorrected = exp(log[HRoriginal]/RDR.
The heterogeneity between PCa risk categories was calculated using
the method by Lunn and McNeil.25
Among PCa cases, cumulative incidence with time since PCa diag-
nosis as the time scale was calculated treating death from causes
other than PCa death as a competing risk.
Cases’ characteristics were compared using the chi-squared test
for categorical variables and the two independent samples t-test for
continuous variables. Data were analysed with STATA release
13 (StataCorp LP, College Station, Texas).
3 | RESULTS
The baseline characteristics of the 431 902 men in the study are given
in Table 1, and according to height and BMI in Tables S1 and S2. Dur-
ing, on average, 28 years (SD 11.7) of follow-up, totalling 12.1 million
person-years, 32 871 men were diagnosed with PCa, of which 6748
died from the disease. Data from the PCa register were available for
27 830 cases, 27 130 of which had sufficient data for cancer risk
categorisation (Table 2). Participants included in each type of analysis
are shown in Figure S2, and HRs for total PCa across levels of height
and BMI for each of these analysis subsets are shown in Table S3.
The shape of associations between height and BMI, and PCa risk
were similar across the five risk categories (Figures S3 and S4). Height
was weakly positively associated with PCa risk up to a height of
175 cm, at which the association flattened out. BMI was positively
associated with risk up to a BMI of about 25 kg/m2, at which the
association became negative.
In the analysis of the full population (Table 3), height was posi-
tively associated with the risk of any PCa (HR per 5 cm, 1.02, 95% CI
1.01-1.03) and with localised intermediate-risk disease (1.03,
1.01-1.05), but not with other PCa risk categories (P for heterogene-
ity = .15). Compared to a BMI of 22.5-24.9 kg/m2, lower BMI and
each higher BMI category were associated with lower risks of
localised low-risk disease (HRs: <22.5 kg/m2, 0.91, 0.86-0.98; ≥30 kg/
m2, 0.57, 0.48-0.65) and localised intermediate-risk disease (HRs:
<22.5 kg/m2, 0.93, 0.88-1.00; ≥30 kg/m2, 0.75, 0.65-0.85). On aver-
age, across the BMI range, these associations were negative (HRs per
5 kg/m2, 0.86, 0.81-0.90 for localised low-risk, and 0.92, 0.88-0.97
for localised intermediate-risk), and BMI was not associated with risks
of more advanced PCa's (P for heterogeneity = .04). Associations with
PCa risk according to tumour stage and grade are shown in Table S4.
Both height and BMI were positively associated with PCa-specific
mortality in the full population (HRs per 5 unit increase, 1.05,
1.02-1.07 and 1.12, 1.08-1.17).
The positive association between height and localised
intermediate-risk PCa, and the negative association between over-
weight/obesity and localised low- and intermediate-risk PCa, were
partially driven by more pronounced associations with PCa's detected
by asymptomatic screening and, for height, also by other symptoms
than LUTS (Figure 1). Characteristics of cases with stage T2 tumours
showed that men with screen-detected PCa's were younger, had less
comorbidities, were more often never smokers, and had a higher edu-
cation and income, than those with LUTS-detected PCa, but did not
differ with regard to their country of birth or family history of PCa
(Table 4).
The cumulative incidence analyses of PCa cases showed
increased risks of PCa-specific mortality and other causes of death
with higher BMI and shorter height (Figures S5 and S6).
In Cox regression analysis of PCa cases (Figure 2), height was pos-
itively associated with the risk of PCa-specific mortality among
localised low- and intermediate-risk PCa combined (HR per 5 cm,
TABLE 1 (Continued)
Baseline characteristic Total (n = 431 902) Noncases (n = 399 031)
Prostate cancer
cases (n = 32 871)
First-degree family history of prostate cancer, n (%)c
No 287 734 (67) 270 806 (68) 16 928 (51)
Yes 6253 (1) 5331 (1) 922 (3)
Missing 137 915 (32) 122 894 (31) 15 021 (46)
aMissing smoking data are almost exclusively for the Construction Workers Cohort for the years 1975 to 1977, during which no smoking information was
collected.
bDetermined by the Swedish Longitudinal integration database for health insurance and labour market studies.
cDetermined from the Swedish Multi-generation Register and the Swedish Cancer Register.
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1.09, 95% CI 1.01-1.18), but not with other risk groups (P for hetero-
geneity = .09). BMI was positively associated with PCa-specific mor-
tality among all cases (HR per 5 kg/m2, 1.13, 1.08-1.20) and in all
separate PCa groups (P for heterogeneity = .14). However, the major-
ity of deaths among men with localised PCa was from causes other
than PCa (Table S5). Whereas height was not associated with the risk
of all-cause mortality among all cases (HR per 5 cm 1.02, 0.99-1.05)
or separately in localised PCa risk categories (HRs per 5 cm 1.09, 0.98
and 1.01), BMI was positively related to all-cause mortality among all
cases (HR per 5 kg/m2 1.17, 1.10-1.22) and in each localised PCa risk
category (localised low-risk, 1.19, 1.02-1.38; intermediate-risk, 1.20,
1.08-1.34; and high-risk, 1.22, 1.06-1.42).
4 | DISCUSSION
In this large prospective study on body size and PCa risk and mortal-
ity, height was positively associated with risk of localised
intermediate-risk PCa, and overweight and obesity were associated
TABLE 2 Clinical characteristics of the 27 830 incident prostate
cancer cases in the study identified in the Swedish National Prostate
Cancer Register
Characteristic
Age at diagnosis, Mean (SD), years 69.2 (8.4)
Categories, n (%)
<65 8240 (30)
65-70 6492 (23)
70-75 5638 (20)
>75 7460 (27)
Charlson comorbidity index, n (%)a
0 (no comorbidity) 22 507 (83)
1 (mild comorbidity) 2669 (10)
≥2 (severe comorbidity) 1954 (7)
Detection mode of the prostate cancer
Asymptomatic health check-up 9827 (35)
Lower urinary tract symptoms 7691 (28)
Other symptoms 6585 (24)
Missing 3727 (13)
Local clinical tumour stage, n (%)
T1a, T1b 1492 (5)
T1c 10 971 (39)
T1 unspecified 46 (<1)
T2 8631 (31)
T3, T4 5995 (22)
Missing 695 (3)
Lymph node metastasis, n (%)
N0, no lymph node metastasis 5074 (18)
N1, lymph node metastasis 878 (3)
Nx, no lymph node extirpation performedb 21 736 (78)
Missing 142 (1)
Bone metastasis, n (%)
M0, no bone metastasis 14 902 (54)
M1, bone metastasis 2619 (9)
Mx, no bone scan performedb 10 167 (37)
Missing 142 (<1)
Tumour differentiation, n (%)c
Low grade 1641 (6)
Intermediate grade 17 766 (64)
High grade 5094 (18)
Gx† 539 (2)
Missing 2790 (10)
PSA at diagnosis, ng/mL, n (%)
<4 2429 (9)
4-9.9 10 818 (39)
10-49.9 9402 (34)
≥50 4342 (15)
Missing 839 (3)
(Continues)
TABLE 2 (Continued)
Characteristic
Cancer risk category, n (%)d
Localised low-risk 7341 (26)
Localised intermediate-risk 7877 (28)
Localised high-risk 6178 (22)
Regionally metastatic/locally advanced 1909 (7)
Distant metastases 3825 (14)
Missing 700 (3)
Primary treatment, n (%)e
Conservative 7529 (27)
Curative 11 225 (40)
Noncurative 7989 (29)
Dead before treatment decision 103 (<1)
Missing 984 (4)
Abbreviation: PSA, prostate cancer-specific antigen.
aBased on discharge diagnoses in the Swedish Patient Register.
bNx, Mx and Gx imply that these were never measured, and the reason for
missing data is unknown.
cClassified according to Gleason grading (n = 24 501) or WHO grade
(n = 7257) into low grade (Gleason score 2-6 or WHO grade 1), intermedi-
ate grade (Gleason score 7 or WHO grade 2) or high grade (Gleason
score ≥ 8 or WHO grade 3).
dLocalised low-risk, T1-2, Gleason score 2-6 and PSA <10 ng/mL; localised
intermediate-risk, T1-2, Gleason score 7 and/or PSA 10 to <20 ng/mL;
localised high-risk, T3 and/or Gleason score 8-10 and/or PSA 20 to
<50 ng/mL; regionally metastatic/locally advanced, T4 and/or N1 and/or
PSA 50 to <100 ng/mL in the absence of distant metastases; distant
metastases, M1 and/or PSA ≥100 ng/mL.
eConservative treatment includes watchful waiting and active surveillance;
curative treatment includes radical prostatectomy and radiotherapy; non-
curative treatment includes all androgen deprivation therapies (orchiec-
tomy, GnRH agonists and antagonists) and antiandrogens.
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with lower risks of localised low- and intermediate-risk PCa's. These
associations were partially driven by PCa's detected by asymptomatic
PSA screening and, for height, also by symptoms other than LUTS. No
associations were found with risk of more advanced PCa's at diagno-
sis. However, BMI was positively associated with PCa-specific mortal-
ity in each PCa risk category.
Differential associations by tumour spread and aggressiveness as
observed in the large study of Genkinger et al7 and in other studies,2-6
have been hypothesised to be influenced by various detection
biases.8-10 Hemodiluted PSA levels in obese men may result in fewer
prostate biopsies, and an enlarged prostate gland in obese men might
cause a cancer to remain undetected during biopsy. A differential
screening behaviour by body size could also result in detection bias.8
In Sweden, opportunistic PSA-screening has increased during the past
decades, as reflected by the increased PCa incidence in Sweden since
the mid-1990s.26 In our study, we used information on detection
mode of the PCa to investigate influence of PCa screening on our
findings. Admittedly, these data contained some misclassifications,22
as evidenced by that LUTS accounted for a sizable cause of detection
among localised low-risk PCa's, which is generally asymptomatic. In
this group, LUTS were likely caused by concomitant benign prostatic
hyperplasia or was wrongly reported by the men to motivate a PSA
test, and the clinical T stage may sometimes have been under-
estimated. However, assuming random misclassification, our results
should correctly indicate the direction of differential associations by
detection mode. Our results suggest that screen-detected PCa, and
for height also detection by symptoms other than LUTS, partially
drove the decreased risk of localised low- and intermediate-risk PCa's
among overweight and obese men, and the increased risk among taller
men. These findings support the hypothesis that normal-weight men,
but also taller men, may undergo PSA testing more frequently and as
a consequence are more often detected with localised PCa.8 Socio-
economic factors associated with body size27 may be one of several
explanations for such differential screening behaviour. Our weak or
null findings for BMI and height in association with LUTS-detected
localised PCa's and more advanced PCa's, and Mendelian
randomisation studies in the field,28,29 speak against a causal role of
body size in PCa risk.
In relation to PCa-specific mortality, height was weakly, positively
related to risk, in support of previous observational studies.3,4 How-
ever, the association was confined to localised low- and intermediate-
risk PCa's which rarely progress to lethal disease, and we found no
F IGURE 1 Hazard ratios (95% confidence intervals) for incident localised prostate cancer assigned a cancer risk category and mode of
detection of the prostate cancer, according to height and body mass index. BMI, body mass index; CI, confidence interval; LUTS, lower urinary
tract symptoms; PCa, prostate cancer. Prostate cancer risk categories were categorised into localised low-risk = T1-T2, Gleason score 2-6 and
PSA <10 ng/mL; localised intermediate-risk = T1-2, Gleason score 7 and/or PSA 10 to <20 ng/mL; localised high-risk = T3 and/or Gleason score
8-10 and/or PSA 20 to <50 ng/mL. Hazard ratios (95% confidence interval) were calculated by Cox regression with attained age as time scale,
stratified on cohort and birth decade, and adjusted for age at study entry, smoking status, healthcare region, country of birth and education. The
hazard ratios of BMI were corrected for the regression dilution ratio of 0.90. Conversion into the uncorrected hazard ratios can be obtained using
the equation HRoriginal = exp(log(HRcorrected) × 0.90). The analysis included 335 134 noncensored men by January 1, 2004, as of which all
three modes of prostate cancer detection shown in the figure were reported to the National Prostate Cancer Register of Sweden
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TABLE 4 Characteristics of men with localised low- or intermediate-risk T2 tumours according to main reason for detection of the prostate
cancer
Characteristic
Asymptomatic
(n = 2066)
LUTS
(n = 1289)
Other
symptoms
(n = 1003)
P for difference,
asymptomatic
vs LUTS
P for difference,
asymptomatic vs LUTS
and other symptoms
Cohort, n (%)
Construction Workers Cohort 1655 (80) 999 (78) 756 (75) .003* .001*
Västerbotten Intervention Programme 211 (10) 192 (15) 104 (10)
Northern Sweden Monica Study 15 (1) 17 (1) 9 (1)
Malmö Diet and Cancer Study 104 (5) 42 (3) 78 (8)
Malmö Preventive Project 81 (4) 39 (3) 56 (6)
Smoking status at baseline, n (%)a
Never smoker 776 (44) 437 (40) 306 (35) .03* <.001*
Ex-smoker 423 (24) 314 (29) 272 (32)
Current smoker 564 (32) 337 (31) 289 (33)
Age at diagnosis, years
Mean (SD) 66.9 (7.1) 70.2 (7.7) 69.0 (7.9) <.001** < .001**
Categories, n (%)
<65 792 (38) 320 (25) 303 (30) <.001* <.001*
65-70 595 (29) 299 (23) 257 (26)
70-75 417 (20) 312 (24) 215 (21)
≥75 262 (13) 358 (28) 228 (23)
Year of diagnosis, mean (SD)b 2011 (5) 2010 (5) 2006 (5) <.001** <.001**
Charlson comorbidity index, n (%)c
0 (no comorbidity) 1819 (88) 1065 (83) 795 (79) <.001* <.001*
1 (mild comorbidity) 167 (8) 131 (10) 121 (12)
≥2 (severe comorbidity) 80 (4) 93 (7) 87 (9)
Gleason score at diagnosis, mean (SD) 6.5 (0.6) 6.5 (0.6) 6.3 (0.8) .08** .07**
PSA at diagnosis, ng/mL, mean (SD) 8.0 (3.9) 8.6 (4.4) 8.8 (4.3) <.001** <.001**
Education closest to diagnosis, n (%)a,d
Pre-upper secondary school <9 years 598 (29) 511 (40) 418 (42) <.001* <.001*
Pre-upper secondary school 9 years 182 (9) 90 (7) 67 (7)
Max. 2 years upper secondary school 684 (33) 379 (29) 287 (28)
3 years upper secondary school 358 (17) 195 (15) 148 (15)
Post-upper secondary school <3 years 151 (7) 62 (5) 54 (5)
Post-upper secondary school ≥3 years 92 (5) 47 (4) 27 (3)
Gross income by main source of income, kSEK/year, mean (SD)e
Work 217 (87) 208 (80) 209 (82) <.001** <.001**
Pension 174 (87) 151 (53) 151 (62) <.001** <.001**
Civil status closest to diagnosis, n (%)a
Unmarried 220 (10) 111 (9) 87 (9) <.001* <.001*
Married/registered partner 1440 (70) 864 (67) 675 (67)
Divorced/divorced partner 305 (15) 200 (15) 150 (15)
Widower/widower of partner 101 (5) 113 (9) 91 (9)
Country of birth, n (%)
Born in Sweden and both parents born in Sweden 1892 (92) 1189 (92) 923 (92) .82* .47*
Other 174 (8) 100 (8) 80 (8)
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TABLE 4 (Continued)
Characteristic
Asymptomatic
(n = 2066)
LUTS
(n = 1289)
Other
symptoms
(n = 1003)
P for difference,
asymptomatic
vs LUTS
P for difference,
asymptomatic vs LUTS
and other symptoms
First-degree family history of prostate cancer at the time of diagnosis, n (%)a,f
No 1622 (95) 847 (95) 553 (95) .49* .57*
Yes 89 (5) 45 (5) 31 (5)
Note: *P value calculated with chi-squared test. **P value calculated with two independent samples t test.
Abbreviations: LUTS, lower urinary tract symptoms; PSA, prostate cancer-specific antigen.
aMissing data were excluded from this table. The number of missing data were 697 for smoking status, 9 for education, 1171 for family history of prostate
cancer, 8 for main source of income and 1 for civil status.
bDetection mode was recorded from 2000 and onwards, with the specification of LUTS as cause for detection recorded as from 2004.
cBased on discharge diagnoses in the Swedish Patient Register.
dDetermined from the Swedish Longitudinal integration database for health insurance and labour market studies.
eNumber of cases per main source of income: work-asymptomatic, 1748; work-LUTS, 950; work-other symptoms, 639; pension-asymptomatic, 87;
pension-LUTS, 139; pension-asymptomatic, 204. For the remaining cases, the main income source was either from income/allowance due to early retire-
ment, sickness, unemployment, social benefits or labour market policy activity.
fDetermined from the Swedish Multi-generation Register and the Swedish Cancer Register.
F IGURE 2 Hazard ratios (95% confidence intervals) for prostate cancer-specific mortality among prostate cancer cases assigned a
cancer risk category, according to height and body mass index. BMI, body mass index; CI, confidence interval. Prostate cancer risk
categories were categorised into localised low-risk = T1-T2, Gleason score 2-6 and PSA <10 ng/mL; localised intermediate-risk = T1-2,
Gleason score 7 and/or PSA 10 to <20 ng/mL; localised high-risk = T3 and/or Gleason score 8-10 and/or PSA 20 to <50 ng/mL. Hazard
ratios (95% confidence interval) were calculated by Cox regression with time since diagnosis as the time scale, stratified on cohort and
birth decade, and adjusted for age at diagnosis, smoking status, healthcare region, country of birth, education at the time of diagnosis,
income closest to diagnosis, source of income closest to diagnosis, civil status closest to diagnosis, Charlson comorbidity index,23 primary
treatment for prostate cancer and prostate cancer risk category (in the total analysis). The hazard ratios of BMI were corrected for the
regression dilution ratio of 0.90. Conversion into the uncorrected hazard ratios can be obtained using the equation HRoriginal = exp(log
(HRcorrected) × 0.90)
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association between height and all-cause mortality. In our and a large
number of other observational studies,12-16 BMI was positively associ-
ated with PCa-specific mortality across all PCa risk categories, and
with all-cause mortality among localised tumours. One Mendelian
randomisation study on PCa cases indicated a positive association
between BMI and all-cause mortality, but not with PCa-specific mor-
tality, however, the analysis was underpowered.29
A relationship between obesity and poor PCa prognosis may have
biological explanations, or may be the result of less successful treat-
ment of obese PCa patients, leading to increased disease recurrence.9
Worse outcomes in obese men undergoing radical prostatectomy, such
as more positive margins, have been frequently reported,30 but data
from studies on nonsurgical treatment are scarce. Potential biological
mechanisms linking obesity with PCa progression include insulin,
insulin-like growth factors, adipokines and sex hormones.3,9,15 Our find-
ing that excess weight is a risk factor for PCa mortality also in localised
disease, which is not likely to be subject to distortion by curative and
palliative treatment, indicates a biological effect of obesity on PCa pro-
gression. This is further supported by a study on the relation between
BMI and PCa progression in patients with low-risk PCa on active sur-
veillance.31 However, it is possible that the net negative association
between BMI and the risk of low-risk PCa, through collider stratifica-
tion bias (selection bias due to the analysis of cases only), causes spuri-
ous positive associations with BMI in prognostic analyses of this
tumour group.32,33 However, the adjustments for many important con-
founders would reduce the risk of collider bias influencing our results,
although uncontrolled factors, such as genetics, could still be involved.
A limitation of our study was the use of BMI rather than more
specific markers of body composition. Strengths include our ability to
investigate body size and PCa across several stages in a large sample,
together with the use of highly valid PCa clinical data.22 Adjustment
was made for the most important potential confounders, including
clinical treatment and comorbidity among cases. Another strength
was the use of measured rather than self-reported body size, and of
demographic factors, and the use of repeated health observations,
which made little difference to the correction of HRs due to the high
regression dilution ratio of BMI, but supported the usability of BMI as
long-term marker of adulthood BMI.
5 | CONCLUSIONS
In this comprehensive study on the relation between height and BMI,
and PCa risk and mortality, no evidence was found for a causal associ-
ation with disease risk, rather it indicated that differential screening
and health-seeking behaviour among men of different body size might
explain such associations. The results further showed a positive asso-
ciation between BMI and PCa-specific mortality, which could either
be due to a biological effect of obesity on PCa progression, or the
result of less successful PCa treatment of obese than normal-weight
men. It remains to be determined whether weight loss and mainte-
nance, together with improved clinical treatment of obese PCa
patients, can improve PCa prognosis in obese men.
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